Pfizer partners with Cipla for five-year brand marketing deal in India

Pfizer Limited has entered into an exclusive supply and marketing agreement with Cipla Limited for the marketing and distribution of four of its brands in India: Corex Dx, Corex LS, Dolonex, and Neksium. This partnership, effective for an initial period of five years, aims to leverage Cipla's extensive customer understanding, distribution reach, and network to ensure wider access for these medicines across the country.

Under the terms, Cipla will hold the sole right to market, distribute, and sell these Pfizer brands, while Pfizer will continue to manufacture, source, and supply the medicines for the Indian market.

The collaboration is expected to lead to a reduction in Pfizer Limited's field force, with the company committing to support impacted colleagues with career transition. The financial implications of this workforce reduction will be disclosed in Pfizer's upcoming financial results.